Business
Viemed Healthcare Announces Third Quarter 2025 Financial Results
LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today ...
About this update from Viemed Healthcare, Inc.
[{"type":"text","content":"LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and nine months ended September 30, 2025.","length":369,"tagName":"p"},{"type":"text","content":"Operational highlights (all dollar amounts are USD):","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenues for the quarter ended September 30, 2025 were $71.9 million, setting a Company record, representing an increase of $13.9 million, or 24.0%, over net revenues reported for the comparable quarter ended September 30, 2024.","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Net income attributable to Viemed for the quarter ended September 30, 2025 totaled $3.5 million, or $0.09 per diluted share.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA for the quarter ended September 30, 2025 totaled $16.1 million, a 15.5% increase as compared to the quarter ended September 30, 2024.","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Net cash provided by operating activities totaled $18.4 million for the quarter and $48.5 million for the trailing twelve months ended September 30, 2025. Free cash flow totaled $12.4 million for the quarter and $23.3 million for the trailing twelve months ended September 30, 2025.","length":282,"tagName":"p"}]},{"val":[{"type":"text","content":"On July 1, 2025, Viemed closed on the strategic acquisition of Lehan's Medical Equipment ("Lehan"). The results of Lehan's operations have been included in the consolidated financial statements since the date of acquisition and were immediately accretive to net income and earnings per share.","length":310,"tagName":"p"}]},{"val":[{"type":"text","content":"During the third quarter of 2025, the Company repurchased and cancelled 1,706,380 common shares under its share repurchase program at a cost of $11.4 million, representing an average buyback price of $6.68 per share.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company increased its ventilator patient count to 12,372 as of September 30, 2025, an increas...